Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT
Posted inClinical Updates Hematology-Oncology news

Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT

A new Blood study links relapse after myeloma ASCT to CSF-1R+ immunosuppressive marrow macrophages and shows that CSF-1R inhibition synergizes with lenalidomide in preclinical models, providing a strong translational rationale for post-transplant combination maintenance.
Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
Posted inHematology-Oncology news Oncology

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and encouraging early survival outcomes.